Soleno Therapeutics
在场
高管
查看带有其 16 名主要高管的组织结构图
Soleno Therapeutics 搜索最多的简介
- Anish Bhatnagar, Chief Executive Officer and Director
- Birgitte Volck, Director
- William Harris, Director
高管在Soleno Therapeutics变化
- Matthew Pauls 曾任 Director, 现升职为 Lead Independent Director (新闻发布的2024八月18号).
- Ernest Mario, Chairman of the Board, 已经离开公司 (新闻发布的2024八月18号).
创建提醒
跟踪 Soleno Therapeutics 的高管变动
生物技术
Soleno Therapeutics 拥有 2,316 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
Soleno Therapeutics 的最新新闻稿
- Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome – Soleno Therapeutics Inc.
- Soleno Therapeutics to Participate in Fireside Chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit – Soleno Therapeutics Inc.
- Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2020 Financial Results – Soleno Therapeutics Inc.
- Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters’ Option to Purchase Additional Shares – Soleno Therapeutics Inc.
- Soleno Therapeutics Added to Russell 3000® Index – Soleno Therapeutics Inc.
- Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters’ Option to Purchase Additional Shares – Soleno Therapeutics Inc.
- Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock – Soleno Therapeutics Inc.
- Soleno Therapeutics Announces Proposed Public Offering of Common Stock – Soleno Therapeutics Inc.
- Soleno Therapeutics Announces Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome – Soleno Therapeutics Inc.
- Soleno Therapeutics Announces Publication Evaluating Potential Role of Activating ATP-Sensitive Potassium Channel in Treatment of Hyperphagic Obesity – Soleno Therapeutics Inc.
- View more press releases Close
通过电子邮件
